Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lilly's move on oral protein delivery

It's been a long time coming, but it's beginning to look as if oral delivery of proteins will be technically feasible. The latest indicator is a $60 million deal by Eli Lilly and Co. to license Emisphere Technologies Inc.'s delivery technology, with a major focus in endocrinology, including growth disorders.

"The issues in oral delivery of proteins have been whether you can deliver proteins

Read the full 632 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers